Radiopharm Theranostics (RADX) Total Debt (2024 - 2025)

Radiopharm Theranostics (RADX) reported Total Debt of $3.6 million for Q2 2025, up 1917.98% year-over-year from $178643.7 in Q2 2024, and up 1917.98% quarter-over-quarter from $178643.7 in Q2 2024.

Radiopharm Theranostics (RADX) Total Debt (2024 - 2025) Analysis & Trends

Radiopharm Theranostics (RADX) has 2 years of Total Debt data on file, last reported at $3.6 million in Q2 2025.

  • Total Debt for Q2 2025 came in at $3.6 million, up 1917.98% year-over-year; the trailing twelve-month figure through Jun 2025 was $3.6 million (up 1917.98% YoY), and the FY2025 annual result was $32.1 million, up 17867.79% from the prior year.
  • Total Debt rose to $3.6 million in Q2 2025 per RADX's latest filing, from $178643.7 in the prior quarter.
  • Over five years, Total Debt peaked at $3.6 million in Q2 2025 and troughed at $178643.7 in Q2 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 319.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Radiopharm Theranostics 5.82 Bn 5.81 Bn - 3.60 Mn

Historic Data

Download Data
DateValue
Jun 30, 2025 3.60 Mn
Jun 30, 2024 178,643.67